clinical trial

Novo Nordisk's CagriSema underperformed Eli Lilly's tirzepatide in weight-loss trials, delivering 20.2% versus 23.6% weight reduction, triggering stock declines amid intensifying obesity drug competition.

Novo Nordisk's stock fell 16% after CagriSema obesity drug failed to match Eli Lilly's tirzepatide in trial, showing weaker weight loss results and jeopardizing approval timeline.

Aligos presented clinical progress for hepatitis B and coronavirus treatments at CROI. Pevifoscorvir showed strong viral suppression, while ALG-097558 provided dosing data for impaired patients.

Inovio Pharmaceuticals faces FDA rejection of its lead drug candidate and mounting cash constraints, raising questions about the biotech firm's long-term viability without revenue-generating products.

Novo Nordisk shares plunged 13% after CagriSema obesity drug trial missed non-inferiority target versus Eli Lilly's tirzepatide, threatening competitive positioning.

Dyne Therapeutics will present five neuromuscular disease presentations at MDA 2026, showcasing cardiopulmonary data from DMD trial and Phase 3 design for myotonic dystrophy treatment.

Redmile Group adds $63M to Nurix stake despite stock decline, betting on promising BTK degrader clinical data and upcoming registrational trials.

Candel Therapeutics raises $100M via public share offering to fund commercialization of its prostate cancer gene therapy and ongoing lung cancer clinical trials.

Candel Therapeutics plans $100M stock offering to fund cancer treatment pipeline development, particularly for prostate and lung cancer therapies.

REGENXBIO faces securities class action alleging false statements about RGX-111 gene therapy program and clinical trial outcomes. Investors from February 2022-January 2026 may recover damages.

Long-acting HIV injectable therapy significantly outperforms daily pills in Phase 3 trial, showing lower failure rates and improved outcomes for patients with adherence challenges.

FDA grants J&J's Rybrevant Faspro breakthrough designation for HPV-negative head and neck cancer, potentially accelerating patient access to this new treatment option.

CervoMed's neflamapimod selected for UK's accelerated EXPERTS-ALS trial platform. The drug will be evaluated in 35-80 ALS patients over 18-24 weeks.

HCW Biologics raised $1.5M through a unit offering and seeks shareholder approval to reduce warrant exercise price from $2.41 to $0.6055 per share.

REGENXBIO faces class action lawsuit alleging false statements about RGX-111 gene therapy trial results, covering securities purchased between February 2022 and January 2026.

Teva and Sanofi report positive Phase 3 results for duvakitug IBD treatment, with over 55% of patients meeting efficacy endpoints. Stock rises 2.85%.

Eli Lilly's Retevmo shows significant benefits in early-stage lung cancer, reducing recurrence risk in Phase 3 trial. Positive results may expand the drug's use beyond advanced-stage disease.

Inventiva raises $172.5M, boosting cash position to €99.3M and extending runway through mid-2027 to fund MASH therapy development.

Law firm sues uniQure for allegedly misrepresenting gene therapy trial status and FDA approval timeline, causing stock to surge 250% then fall 49% after FDA reversal.

Vistagen faces securities class action over alleged misleading statements about drug fasedienol. Investors who purchased stock April 2024-December 2025 can join by March 16, 2026 deadline.